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Tumor cells influence their environment by releasing various substances such as cytokines and chemokines. 
Studies over the past few years have shown that microvesicles (MVs) secreted by tumor cells contain proteins, 
mRNAs, and microRNAs (miRNAs) that play important roles in intercellular crosstalk. Recently, we reported 
an exciting finding that tumor cells can manipulate the host immune response via secreting an important 
oncomir, miR-214, through a pathway involving MVs. As an extension of this finding, we showed that the 
delivery of miR-214 antisense oligonucleotides via MVs can significantly inhibit tumor-induced immune escape 
and tumor growth, which provides a novel, effective approach for tumor treatment. 
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Tumor cell communication is a complex and dynamic 
process involving multiple mechanisms that allow tumor 
cells to manipulate their environment [1]. Tumors secrete a 
diversity of signaling molecules to control the behavior of 
immune cells, fibroblasts, vascular tissues, and surrounding 
extracellular matrix [2]. Among the factors contributing to 
tumorigenesis, the failure of the immune system to protect 
against tumor cells is one of the main factors by which 
tumors survive, grow, proliferate, and metastasize [3]. 
However, the detailed mechanism of tumor immune escape 
remains to be elucidated. 
MicroRNAs (miRNAs) are a class of small noncoding 
RNA that are frequently dysregulated in cancers [4]. Once 
thought to only exist in intracellular space, miRNAs have 
now been demonstrated to be stably present in serum, urine, 
saliva, and other bodily fluids [5 ,6]. A significant amount of 
these miRNAs exist in extracellular environment in a form 
that is enclosed in small membranous vesicles named 
microvesicles (MVs, particularly exosomes and shedding 
vesicles) [7]. Through MV-cell interactions, MVs can actively 
deliver miRNAs to recipient cells, in which exogenous 
miRNAs can inhibit the expression of their target genes and 
manipulate recipient cell function. Thus, miRNAs secreted 
through MVs are active and can function as novel signaling 
molecules to mediate cell-to-cell communication [8].  
In a recent study [9], we provided evidence indicating that 
tumor cells actively secrete miRNAs to exert a suppressive 
effect on immune cells, particularly regulatory T cells 
(Tregs), which is a subtype of CD4+ T cells that plays a 
pivotal role in tumor immune escape. Specifically, we 
observed increased secretion ofmiR-214, an important 
oncogenic miRNA, in a variety of human cancers and mouse 
tumor models. Tumor-secreted miR-214 was sufficiently 
transfered to recipient CD4+ T cells via MVs, and exogenous 
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miR-214 downregulated its target gene, phosphatase and 
tensin homolog (PTEN), resulting in an expansion of 
functional Tregs, as PTEN is a negative regulatory factor of 
Treg homeostasis in vivo and Treg expansion ex vivo [10]. 
Because Tregs are potent inducers of tumor immune escape 
[11], the increased Treg population mediated by tumor-derived 
miR-214 led to host immune tolerance, therefore causing 
immune escape and rapid growth of the tumor cells (Figure 
1).  
The function of secreted miRNAs in tumorigenesis has 
only been investigated recently. Several studies have 
revealed that tumor-secreted miRNAs can participate in 
tumor progression by inducing tumor formation, promoting 
mesenchymal-to-epithelial transition, or destroying vascular 
endothelial barriers to promote metastasis [12, 13]. These 
studies focused on investigating the crosstalk between 
malignant cells and nontumorigenic epithelial cells or on 
strongly and weakly metastatic cancer cells. Our study raises 
a novel standpoint that tumor cells can actively manipulate 
the antitumor efficacy of immune cells and change the 
property of surrounding cells in the tumor microenvironment. 
Our thought-provoking work reveals the importance of 
tumor-secreted miRNA as a novel regulator of cancer 
immunology. 
Because immune escape is always correlated with 
tumorigenesis, the modulation of the immune system for 
tumor therapy is an intensive area of research [14]. However, 
immune-based therapy is often difficult to apply in practice 
due to the organism’s self-defense. Because MVs are natural 
nanocarriers derived from endogenous cells, they will be 
better tolerated by the immune system [15]. Furthermore, MVs 
are thought to be an ideal delivery system due to their small 
size and abilities to cross biological membranes and protect 
their cargo from degradation. By employing cell-derived 
MVs to deliver anti-miR-214 antisense oligonucleotides to 
peripheral CD4+ T cells, we successfully reversed the 
downregulation of PTEN in CD4+ T cells and repressed the 
upregulation of Treg population induced by tumor cells. As 
anticipated, the MV-delivered anti-miR-214 significantly 
decreased the growth of implanted and spontaneous tumors. 
Moreover, proteins that are indispensable for miRNA 
function, such as Argonaute 2 (AGO2) [16, 17], were found to 
be bound to miRNAs in MVs. Thus, MVs have the natural 
advantage to traverse biological barriers and transport 
functional miRNAs across cells. Therefore, the miRNA 
delivery system based on MV carrier may provide a novel 
method for gene therapy.  
Taken together, our study demonstrates for the first time 
that tumor cells can actively regulate immune cell function 
via secreting tumor-specific miRNAs. This study 
Figure 1. Working model of tumor-secreted miR-214 on the induction of Tregs. Tumor cells secrete miR-214 via MVs to the 
extracellular environment. Secreted miR-214 is then delivered into peripheral CD4+ T cells. After the MVs enter the recipient CD4+ T cells, 
miR-214 inhibits PTEN protein expression and facilitates Treg expansion, which, in turn, results in host immune suppression and tumor 
growth. 
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significantly extends the role of miRNAs and opens up new 
avenues for investigating the secreted miRNA-mediated 
interactions of tumor cells and immune cells. However, these 
interactions are still largely unknown, especially regarding 
the specificity and sufficiency of the secretion of the miRNA 
and its special recognition by target cells. Overall, more 
extensive investigations are required in the future to 
determine the application potential of secreted miRNAs as 
attractive molecules in tumor therapy. 
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